Approval · Notice of Compliance 17167 · 2015
ACT RISPERIDONE: Notice of Compliance 17167
Issued August 5, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17167
- Date
- August 5, 2015
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Antipsychotic agent
- Canadian reference product
- RIPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT RISPERIDONE | 02282585 | Cancelled Post Market |
| ACT RISPERIDONE | 02282593 | Cancelled Post Market |
| ACT RISPERIDONE | 02282607 | Cancelled Post Market |
| ACT RISPERIDONE | 02282615 | Cancelled Post Market |
| ACT RISPERIDONE | 02282623 | Cancelled Post Market |
| ACT RISPERIDONE | 02282631 | Cancelled Post Market |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB